The stock of Illumina Inc. (NASDAQ:ILMN) last traded at $202.20, up 0.28% from the previous session.
ILMN stock price is now -6.13% away from the 50-day moving average and -13.31% away from the 200-day moving average. The market capitalization of the company currently stands at $31.72B.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
With the price target reduced from $200 to $180, Citigroup Downgraded its rating from Neutral to Sell for Illumina Inc. (NASDAQ: ILMN). On December 07, 2022, RBC Capital Mkts recently initiated its ‘Outperform’ rating on the stock quoting a target price of $282, while ‘SVB Leerink’ rates the stock as ‘Outperform’.
In other news, TOUSI SUSAN H, SVP, Chief Commercial Officer sold 500 shares of the company’s stock on Dec 06. The stock was sold for $106,315 at an average price of $212.63. Upon completion of the transaction, the SVP, Chief Commercial Officer now directly owns 39,162 shares in the company, valued at $7.92 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 08, SVP, Chief Technology Officer Aravanis Alexander sold 361 shares of the business’s stock. A total of $78,698 was realized by selling the stock at an average price of $218.00. This leaves the insider owning 2,857 shares of the company worth $0.58 million. Insiders disposed of 38,427 shares of company stock worth roughly $7.77 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ILMN stock. A new stake in Illumina Inc. shares was purchased by BALYASNY ASSET MANAGEMENT LLC during the first quarter worth $134,943,000. ALYESKA INVESTMENT GROUP, L.P. invested $109,684,000 in shares of ILMN during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Illumina Inc. valued at approximately $100,890,000. CASDIN CAPITAL, LLC acquired a new stake in ILMN for approximately $77,847,000. SENATOR INVESTMENT GROUP LP purchased a new stake in ILMN valued at around $50,550,000 in the second quarter. In total, there are 1,373 active investors with 91.10% ownership of the company’s stock.
With an opening price of $199.29 on Friday morning, Illumina Inc. (NASDAQ: ILMN) set off the trading day. During the past 12 months, Illumina Inc. has had a low of $173.45 and a high of $428.00. As of last week, the company has a debt-to-equity ratio of 0.26, a current ratio of 0.90, and a quick ratio of 0.70. The fifty day moving average price for ILMN is $215.36 and a two-hundred day moving average price translates $232.63 for the stock.
The latest earnings results from Illumina Inc. (NASDAQ: ILMN) was released for Jul, 2022. According to the Diagnostics & Research Company, earnings per share came in at $0.57, missing analysts’ expectations of $0.65 by -0.08. This compares to $2.07 EPS in the same period last year. The net profit margin was -88.40% and return on equity was -42.80% for ILMN. The company reported revenue of $1.11 billion for the quarter, compared to $1.11 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.63 percent. For the current quarter, analysts expect ILMN to generate $1.11B in revenue.
Illumina Inc.(ILMN) Company Profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
